selected publications
- Corrigendum: Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies. Frontiers in immunology. 2023 Article GET IT
- Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies. Frontiers in immunology. 2023 Academic Article GET IT
-
Papillary Dermal Elastolysis Secondary to Combination Nivolumab and Cabiralizumab Therapy: Histiocytes and Dermal Mucin as Clues to the Diagnosis.
2021
GET IT
Times cited: 1 -
Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy.
Cell reports.
2021
Academic Article
GET IT
Times cited: 23 -
The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials.
Journal of pancreatology.
2020
Academic Article
GET IT
Times cited: 2 -
Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
Cancer immunology research.
2017
Academic Article
GET IT
Times cited: 110 -
Patient-derived tumor xenografts: transforming clinical samples into mouse models.
Cancer research.
2013
Review
GET IT
Times cited: 502 -
Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).
Oncotarget.
2011
Academic Article
GET IT
Times cited: 15 -
Second-generation shRNA libraries covering the mouse and human genomes.
Nature genetics.
2005
Academic Article
GET IT
Times cited: 539 -
Synthetic shRNAs as potent RNAi triggers.
Nature biotechnology.
2004
Letter
GET IT
Times cited: 371